,0,1
0,wall street journal,9.0
1,executive officer,9.0
2,health authority,9.0
3,undue reliance,9.0
4,foreign objects,9.0
5,treasury yield curve,9.0
6,vertically integrated biopharmaceutical,9.0
7,revisions,8.777777777777779
8,estimation processes,8.6
9,significant setbacks,8.46875
10,significant improvement,8.46875
11,physician specialists,8.35
12,growth companies,8.256916996047432
13,home center properties,8.2
14,arm study,8.196428571428571
15,source plasma,8.19047619047619
16,ii dose,8.166666666666666
17,collaboration opportunities,8.125
18,security holders,8.125
19,rata percentage,8.10344827586207
20,administrative expenses,8.09958071278826
21,partnership agreements,8.0625
22,accounting pronouncements,8.05
23,measured baselines,8.03921568627451
24,response letter,7.974025974025974
25,public companies,7.951000690131124
26,confidential disclosures,7.945945945945946
27,shelf registration statement,7.944444444444445
28,public offering,7.93887200270179
29,venture debt lenders,7.93796992481203
30,leasehold improvement loan,7.933835845896148
31,clinical trials,7.915032679738562
32,clinical trials,7.915032679738562
33,syncytial virus,7.912698412698413
34,syncytical virus,7.912698412698413
35,immune globulins,7.885245901639344
36,donor plasma,7.876190476190477
37,plasma collection center,7.873160173160174
38,investor relations fees,7.871844660194174
39,plasma collection increases,7.865467865467866
40,dividend yield,7.864864864864865
41,warning letter,7.8573189522342055
42,clinical stages,7.842034805890227
43,specialty plasma,7.833333333333334
44,accounting policies,7.8277777777777775
45,gross proceeds,7.80952380952381
46,human plasma,7.793263646922183
47,advisory council,7.7894736842105265
48,collection supplies,7.7885447885447885
49,public companies,7.7605244996549345
50,capital outlays,7.752232142857142
51,diminished liquidity,7.75
52,alternative processes,7.733333333333333
53,intercompany transactions,7.71875
54,clinical trials,7.715032679738562
55,proprietary microneutralization,7.708333333333334
56,predecessor product candidate,7.690480118792279
57,specialty plasma,7.658008658008658
58,enrollment rates,7.647058823529411
59,certifications,7.619402985074627
60,traded options,7.611111111111111
61,party contractor capabilities,7.602941176470589
62,vendor payments,7.597389558232932
63,material plasma,7.590225563909774
64,antibody levels,7.585690045248869
65,equity offerings,7.583843329253366
66,human plasma,7.582737331132709
67,inspection issues,7.58199427690953
68,annual periods,7.571586879432624
69,clinical trial,7.551587301587302
70,immune globulin,7.532304725168756
71,fixed obligations,7.524338624338624
72,plasma collections,7.519047619047619
73,preclinical studies,7.515151515151516
74,orthe securities act,7.5033444816053505
75,pneumonia type 19a,7.5
76,humoral immunodeficiency,7.5
77,authorization safety study,7.5
78,milestone payment,7.49631751227496
79,reporting periods,7.49612496389718
80,fractionation,7.488888888888889
81,pharmaceuticals corporation,7.483851674641148
82,vendors,7.4661487236404
83,source plasma,7.455182072829132
84,fold increases,7.4423076923076925
85,plasma collection centers,7.43982683982684
86,additional plasma,7.427409988385598
87,public offering,7.4249831138129005
88,clinical trials,7.415032679738562
89,ranging trial,7.407142857142857
90,principal balance,7.4066012488849235
91,debt financing,7.404186141028246
92,balance sheet arrangements,7.4
93,accelerated filer,7.4
94,financial position,7.394953966896413
95,average number,7.392857142857143
96,regulatory approvals,7.387878787878789
97,immune system,7.385245901639344
98,significant risks,7.381793478260869
99,interest rate,7.376602564102564
100,biopharmaceutical company,7.359649122807017
101,specialty immunoglobulin company,7.359649122807017
102,specialty treatment organizations,7.357142857142858
103,common stock,7.353108411698045
104,reporting periods,7.345483938256153
105,external funding,7.337590361445782
106,specialty sales force,7.30952380952381
107,net losses,7.3089473684210535
108,service period,7.304032258064516
109,dilutive securities,7.275852675166176
110,growth company,7.268740031897927
111,future policy,7.262455226310648
112,patent application,7.258479532163743
113,byadma biocenters,7.254237288135593
114,substantial amounts,7.248251748251748
115,facility fee,7.23650622082193
116,collection facilities,7.2356601731601735
117,annual meeting,7.208333333333333
118,final payment,7.1991170936459685
119,business requirements,7.195415695415695
120,fiscal years,7.194836956521739
121,deposits,7.192982456140351
122,contract drug substance,7.188207547169812
123,biotechnology industry,7.184873949579832
124,stock options,7.180429056838973
125,stock options,7.180429056838973
126,treasury stock method,7.135231316725978
127,term fee payment,7.129175859957428
128,services agreement,7.127503337783711
129,regulatory approval,7.106132756132756
130,scientific investigators,7.0942028985507255
131,business startups,7.094017094017094
132,trough levels,7.081196581196582
133,business combinations,7.072039072039072
134,transition period,7.0706989247311824
135,common stock,7.064972818477706
136,financing alternatives,7.058251022106444
137,plasma center expenses,7.053548966756514
138,potential forfeitures,7.033465764238478
139,performance obligations,7.030261969286359
140,initial term,7.008951005025126
141,employee options,7.007440476190476
142,equity offering,7.007189569758499
143,increased costs,7.00637573334814
144,stock options,6.999814650059312
145,debt facility,6.999680602194349
146,access,6.994047619047619
147,blood plasma,6.99293688767373
148,antibody titers,6.989087301587302
149,financial information,6.986667808610254
150,cash runway,6.98015873015873
151,tax assets,6.9694308943089425
152,financial statements,6.967681239623685
153,capital stock,6.956470723505639
154,iii study,6.945
155,allotment option,6.936655405405405
156,outstanding debt,6.935548617305976
157,private placement,6.921052631578947
158,regulatory approvals,6.918491032776748
159,potential commercialization,6.917568766637089
160,plasma supply agreement,6.916880627161001
161,capital requirements,6.916056270536692
162,monthly cost,6.90595954073264
163,bacterial infections,6.9
164,party contract manufacturers,6.894720152211828
165,cumulative losses,6.893233082706768
166,common stock,6.8837206565960045
167,development services,6.876712328767123
168,net losses,6.87561403508772
169,georgia plasma center,6.86584564860427
170,payment arrangements,6.8637377510692446
171,clinical data,6.8544061302682
172,drug product,6.847089314194578
173,reporting period,6.838345983554712
174,product candidate,6.8333372616494215
175,titer rsv plasma,6.833333333333334
176,adequate quantities,6.82111801242236
177,total principal,6.817900683913172
178,final approval,6.813392857142857
179,financial payments,6.795886367828814
180,term liquidity,6.790201005025126
181,debt liability,6.789745447957243
182,party transactions,6.783664068036853
183,manufacturing scale,6.779539800995025
184,interest expense,6.776795387710881
185,equity financing,6.776597275336417
186,production costs,6.763518590490996
187,compensation expense,6.763454068013629
188,recurring adjustments,6.759150326797386
189,contract testing laboratory,6.756957547169812
190,licensing arrangements,6.75182436611008
191,future results,6.74412501491113
192,financial condition,6.742194677992545
193,forfeiture rate,6.739583333333334
194,additional equity,6.733057828917159
195,amount,6.732300884955752
196,revenue recognition,6.723391812865497
197,expenses,6.722186076772934
198,stock options,6.718564650059312
199,accounting policies,6.716666666666667
200,warning letter,6.716135173726796
201,test plasma donors,6.713564213564213
202,measured specific anti,6.705882352941177
203,acquisition agreement,6.70542541570579
204,tax benefits,6.701294065149487
205,backend fees,6.694813847869245
206,common stock,6.686441745031379
207,equity commitment,6.685438781298112
208,tax liabilities,6.68503144654088
209,additional capital,6.6796421312427405
210,financing costs,6.679011915140947
211,consulting fees,6.671217700946526
212,transition services agreement,6.669170004450378
213,term loan,6.655855032739455
214,additional financing,6.6456965979765545
215,debt lender,6.642515379357485
216,term loan tranches,6.64070351758794
217,term loans,6.640201005025126
218,methods,6.639676113360324
219,fda approval,6.622267929859553
220,common stock,6.619775078364712
221,employee stock options,6.611421792916454
222,term loan,6.607370184254607
223,rent expense,6.593386405388855
224,indebtedness,6.592306650413111
225,bears interest,6.585444027517198
226,plasma biologics,6.581389565171863
227,clinical studies,6.577482138457748
228,clinical trials,6.565032679738563
229,independent auditors,6.564102564102565
230,outstanding issues,6.563054882970136
231,adverse effect,6.559008632692843
232,consulting services,6.550871542250853
233,compensation stock,6.54938815225686
234,fasb issued asu,6.540388526544638
235,end fees,6.529050868619896
236,prepayment fees,6.527243721227038
237,balance sheet classification,6.526666666666667
238,debt discount,6.5265875532204
239,equity incentive plan,6.526427061310782
240,term loan,6.51570351758794
241,future commercialization,6.515159128082873
242,accounting standards,6.504545454545454
243,additional funds,6.503600464576074
244,biologics license application,6.492493304913373
245,payment accounting,6.480404417735911
246,identifiable assets,6.4753958065896455
247,diligence fees,6.465784054133568
248,notes thereto,6.464130623588675
249,testing costs,6.464045698924731
250,prepaysa loan,6.460151635369831
251,regulatory activities,6.4579545454545455
252,quality management systems,6.4561403508771935
253,senior debt,6.454453441295547
254,significant revenue,6.447697368421053
255,cash flow,6.444444444444445
256,compensation expense,6.442325849615388
257,registration statement,6.4319444444444445
258,debt financings,6.430936676730188
259,company,6.4263157894736835
260,granted biotest ag,6.425759981851179
261,increased quantities,6.422077922077921
262,common stock,6.4218107017743815
263,capital resources,6.418898809523808
264,georgia lease,6.410585404971933
265,financial payment,6.406306444206337
266,expenses,6.40442615973897
267,potentially significantly reduce,6.402974828375286
268,bank credit facility,6.401357872292673
269,overhead expenses,6.377358490566038
270,cash flows,6.376262626262626
271,manufacturing processes,6.369817578772802
272,discovery research programs,6.369047619047619
273,party contract manufacturer,6.3661487236404
274,period,6.365381606964382
275,interim periods,6.354237439656714
276,regulatory approval,6.328354978354978
277,globulin products,6.326422372227579
278,increased sales,6.3238095238095235
279,fda approval,6.322751021646992
280,financial statements,6.311270983213429
281,net proceeds,6.310952380952381
282,titer rsv antibodies,6.300000000000001
283,interim periods,6.2996893046132225
284,increased expenses,6.294409181810278
285,exercise price,6.292014880406591
286,loan agreement,6.286206908547584
287,derived product,6.281613123718387
288,operations,6.271727111897391
289,term loan,6.27033314721757
290,securities exchange act,6.268050363958292
291,impairment test,6.265151515151515
292,debt issue costs,6.25965451262565
293,license agreement,6.249955552658247
294,property position,6.245129870129869
295,period balances,6.240480069512327
296,net cash,6.209059829059829
297,financial statements,6.206369022429115
298,validation services,6.199519884047469
299,groups,6.166666666666666
300,important factors,6.16
301,fda approves,6.158915922389898
302,assets,6.148941664663086
303,drug product manufacturing,6.139129115189602
304,rsv antibody,6.132878151260504
305,acceleration,6.131336405529954
306,existing accounts,6.128071253071253
307,related expenses,6.12474804879897
308,adverse events,6.12037037037037
309,funding date,6.120116959064327
310,contract manufacturing agreement,6.0946554478533095
311,term loan,6.091923029783062
312,development services,6.082756284811079
313,planning activities,6.08198051948052
314,states subsidiary,6.076923076923077
315,office administration,6.066666666666667
316,principal amount,6.050371060394349
317,acquisition fees,6.046195309544824
318,loan amount,6.039325136649001
319,subsidiary,6.037365924205407
320,loan amount,6.034022909713688
321,equity interest,6.02513887581207
322,product development,6.015468309628368
323,administrative expenses,6.0106918238993705
324,theoriginal lsa,6.005990586221651
325,commencement date,5.989936080511355
326,accounting standard,5.986026936026935
327,common stock,5.984687359066466
328,net loss,5.971666666666667
329,baseline rsv titers,5.968253968253968
330,period earnings,5.964746543778801
331,debt liability,5.960086386178212
332,additional staff,5.951219512195122
333,operating expenses,5.947533929162529
334,loan balance,5.943639767464775
335,compensation cost,5.930285867788946
336,interest rate,5.926602564102565
337,ag license,5.907667876588022
338,business adma biologics,5.891523875306174
339,term loan,5.89070351758794
340,debt securities,5.883622098725073
341,georgia,5.880867250465354
342,plasma inventories,5.867494824016562
343,modification,5.865384615384615
344,fees,5.861480514535911
345,interest expense,5.861210972126465
346,actual forfeitures,5.857011409642988
347,early adoption,5.852777777777778
348,total assets,5.847682455415098
349,total revenues,5.8352850539291214
350,costs,5.834347737877866
351,entities,5.830746187363834
352,retrospective adoption,5.829914529914529
353,license agreement,5.825811608460403
354,term loan tranche,5.807370184254607
355,aggregate amount,5.7735203971508735
356,deferred revenue,5.768038277511962
357,earlier application,5.76353046594982
358,gaap require difficult,5.762640901771336
359,option model,5.759821981196027
360,party manufacturing vendors,5.756575180364164
361,development segment,5.755500207555002
362,adma biocenters,5.717527867525244
363,debt issuance costs,5.704098957070094
364,additional equity,5.7022455039871875
365,payment awards,5.697071084402578
366,equity issuance costs,5.678919729932483
367,impairment loss,5.658333333333333
368,fda approval,5.644490152081775
369,plasma development operations,5.639667510839953
370,oxford finance,5.58235294117647
371,adma biocenters,5.575827462666944
372,adma,5.571590174531351
373,term assumptions,5.5388686867914
374,bla approval,5.537558120891454
375,hercules loan,5.515846427906729
376,license revenues,5.499521531100479
377,period presentation,5.498079877112135
378,scale back,5.484848484848484
379,market conditions,5.483734751329371
380,input assumptions,5.459199642298234
381,product revenue cost,5.433832381540361
382,column,5.412121212121212
383,certified georgia,5.35632183908046
384,commercialization activities,5.309168133656625
385,valuation allowance,5.3076923076923075
386,drug products,5.3066176470588236
387,plasma,5.265664160401002
388,sales,5.262531328320802
389,default provisions,5.260989010989011
390,corporate purposes,5.256140350877193
391,additional indebtedness,5.249356158157855
392,events,5.215099715099715
393,note payable due,5.205563921692955
394,subject receiving ivig,5.200799200799201
395,losses,5.178947368421053
396,letter,5.1454545454545455
397,amounts,5.134615384615385
398,stock,5.085082224831156
399,management,5.059912854030501
400,approval,5.051587301587301
401,research,5.0397851050474465
402,final payment,4.9950354609929075
403,patients,4.989583333333333
404,potentially cease,4.984962406015038
405,projected growth,4.980519480519481
406,normal source,4.9789915966386555
407,annual periods,4.977836879432624
408,titer plasma,4.976190476190476
409,accounting guidance,4.970029347028613
410,market research costs,4.968509984639017
411,balance sheet,4.966666666666667
412,retrospective adoption,4.966666666666667
413,bla resubmission,4.960781294114628
414,public companies,4.951000690131125
415,center staff,4.9222222222222225
416,private placement,4.921052631578947
417,clinical trials,4.915032679738562
418,previous debt,4.880277617119722
419,options,4.864583333333334
420,options,4.864583333333334
421,potential investigational,4.863945578231293
422,facility fee,4.846675712347354
423,traded options,4.833333333333334
424,forfeiture rate,4.833333333333334
425,gross proceeds,4.809523809523809
426,entities,4.805147058823529
427,potential approval,4.804421768707483
428,donor collections,4.8
429,alternative future,4.797590361445783
430,human plasma,4.793263646922183
431,party manufacturers,4.781512605042017
432,requirements,4.776737967914439
433,final product,4.772089314194577
434,private companies,4.768878718535469
435,early application,4.7555555555555555
436,plasma centers,4.742857142857143
437,full force,4.736263736263735
438,capital,4.728422619047619
439,fasb issued,4.715646258503401
440,specific dates,4.705882352941177
441,principal balance,4.694736842105263
442,product candidate,4.690480118792278
443,antibody profile,4.6875
444,initial application,4.686111111111111
445,approval requirements,4.682900432900433
446,financial payments,4.661270983213429
447,financing alternatives,4.66066066066066
448,hyperimmune globulin,4.647058823529411
449,increased headcount,4.642857142857142
450,entire study,4.625
451,pediatric study,4.625
452,consulting fees,4.616672246401071
453,future financing,4.613806577661999
454,revenue recognition,4.612280701754386
455,financial reporting,4.612251375370292
456,debt liability,4.609022556390977
457,financial payment,4.6063064442063375
458,fiscal years,4.601086956521739
459,clinics,4.6
460,interim periods,4.59793491864831
461,commercial production,4.5875
462,similar events,4.587301587301587
463,clinical trial,4.551587301587302
464,transition relief,4.541666666666666
465,annual assessments,4.541666666666666
466,immune globulin,4.532304725168756
467,potential indications,4.530612244897959
468,interim reporting,4.529411764705882
469,clinical programs,4.527777777777779
470,titers,4.521367521367521
471,expenses,4.520215633423181
472,capital requirements,4.518465909090909
473,applicableloan prepaid,4.515151515151516
474,net proceeds,4.51095238095238
475,lenders warrants,4.504098360655737
476,securities,4.503344481605351
477,streptococcus,4.5
478,financing fees,4.48806087641039
479,based payments,4.485368956743002
480,access capital,4.484375
481,human resources,4.483739837398374
482,plasma transportation,4.476190476190476
483,employee options,4.476190476190476
484,plasma,4.476190476190476
485,procure plasma,4.476190476190476
486,financial position,4.4718770438194895
487,pidd patients,4.469175170068027
488,stock options,4.468564650059312
489,balance,4.466666666666667
490,directly related,4.46643717728055
491,outstanding warrants,4.465962767435398
492,significant amount,4.451050884955752
493,supply agreements,4.447115384615385
494,future performance,4.446370849250661
495,commercialize ri,4.445378151260504
496,clinical evaluations,4.444444444444445
497,reporting unit,4.439075630252101
498,ongoing discussions,4.4375
499,subsequent periods,4.4361702127659575
500,fees,4.434006822356337
501,dilutive securities,4.433747412008282
502,collaborative arrangements,4.433333333333334
503,financial markets,4.4264224983649445
504,specific date,4.419332645338837
505,initial term,4.415201005025126
506,based compensation,4.414156835530881
507,financial resources,4.411270983213429
508,cash balance,4.411111111111111
509,administrative services,4.404761904761905
510,debt financing,4.404186141028246
511,production,4.4
512,cumulative effect,4.4
513,regulatory consulting,4.3993730407523515
514,foreseeable future,4.397590361445783
515,expenses,4.392510005717552
516,credit markets,4.392344497607656
517,additional periods,4.387389724961079
518,material forfeitures,4.385964912280702
519,immune system,4.385245901639344
520,debt securities,4.383622098725073
521,equity financing,4.379006913890635
522,service providers,4.375
523,compensation expense,4.373623559539052
524,consulting expense,4.372996600291403
525,total amount,4.372131393430328
526,adverse events,4.37037037037037
527,fiscal year,4.367592592592592
528,substantial doubt,4.363636363636363
529,costs,4.363518590490996
530,equity securities,4.358442871587462
531,plasma sales,4.357142857142858
532,common stock,4.353108411698045
533,development plasma,4.3529028049575995
534,debt discount,4.345864661654135
535,financial condition,4.3446043165467625
536,annual report,4.341666666666667
537,losses,4.339816933638444
538,finished product,4.338755980861244
539,increased inventories,4.338509316770186
540,proprietary technology,4.333333333333334
541,libor rate,4.333333333333334
542,unvested options,4.333333333333334
543,primary endpoint,4.333333333333334
544,scientific affairs,4.333333333333334
545,rsv plasma,4.333333333333334
546,voting class,4.333333333333334
547,adverse conditions,4.331723027375201
548,regulatory approval,4.328354978354978
549,potential products,4.324729891956783
550,expenses,4.324167001204335
551,clinical development,4.321156773211568
552,fda focused,4.320680628272251
553,normal donors,4.3202614379084965
554,clinical safety,4.319444444444445
555,office space,4.316666666666666
556,term fees,4.3120456652193
557,jobs,4.3076923076923075
558,ongoing basis,4.305921052631579
559,rsv titers,4.301587301587302
560,period,4.296679316888046
561,financial performance,4.293384804351641
562,debt loan,4.288472437374844
563,scholes model,4.285714285714286
564,requested documentation,4.285714285714286
565,license fees,4.285002554931017
566,material misrepresentations,4.280701754385965
567,existing debt,4.27887901572112
568,subsequently borrowed,4.276923076923078
569,drug administration,4.275
570,approval,4.273809523809524
571,approval,4.273809523809524
572,common virus,4.273432650527623
573,auditing fees,4.271844660194175
574,commercial programs,4.270833333333334
575,existing resources,4.257575757575758
576,operating costs,4.2529711375212225
577,assay development,4.251712328767123
578,negative pledge,4.25
579,modification accounting,4.25
580,based biologics,4.236926589141756
581,united states,4.230769230769231
582,prior loan,4.230132142192444
583,current debt,4.223684210526315
584,expenses,4.222186076772934
585,licensing arrangements,4.221212121212121
586,loan facility,4.219905497637441
587,premium price,4.219512195121951
588,high titer,4.217948717948718
589,common area,4.217877094972067
590,drug product,4.213755980861244
591,administrative expenses,4.210691823899371
592,principal amount,4.2103710603943485
593,blood plasma,4.203463203463204
594,whichwe,4.2
595,regulatory issues,4.197402597402597
596,adjustments,4.194444444444445
597,due diligence,4.193939393939393
598,previous submissions,4.1923076923076925
599,existing loan,4.191411603471905
600,adma biocenters,4.19121207805156
601,commercial infrastructure,4.1875
602,commercial viability,4.1875
603,amount,4.186382517608813
604,planned improvements,4.184615384615384
605,transportation costs,4.182795698924731
606,security agreement,4.18107476635514
607,building related,4.1807228915662655
608,full exercise,4.176113360323886
609,manufacturing capabilities,4.175373134328359
610,future events,4.175368139223561
611,additional staff,4.173441734417344
612,cash position,4.171717171717171
613,deferred taxes,4.168888888888889
614,additional financing,4.167435728411338
615,commercially viable,4.166666666666666
616,low dose,4.166666666666666
617,payments,4.166666666666666
618,renal impairment,4.166666666666666
619,adma biomanufacturing,4.159197012138189
620,increased cost,4.158986175115207
621,related information,4.145008605851979
622,term loan,4.14070351758794
623,product candidates,4.138755980861244
624,product applications,4.138755980861244
625,product,4.138755980861244
626,scommon stock,4.135231316725978
627,itscommon stock,4.135231316725978
628,exemption,4.134615384615385
629,interest expense,4.133938244853738
630,debt disclosures,4.133915870757976
631,adequate funds,4.133333333333334
632,characteristics,4.133333333333333
633,risks,4.130920573232936
634,net realizable,4.13
635,related disclosures,4.126668837512211
636,cash flows,4.126262626262626
637,total revenues,4.1261941448382125
638,security prices,4.125
639,facility,4.119402985074627
640,boca facility,4.119402985074627
641,plasma storage,4.119047619047619
642,commercial planning,4.116071428571429
643,additional equity,4.114010209869541
644,contract filler,4.113207547169811
645,commercial manufacturing,4.112873134328359
646,prices,4.111111111111111
647,capital,4.109375
648,capital contribution,4.109375
649,interest,4.105769230769231
650,adma biologics,4.1051990889813865
651,adma biologics,4.1051990889813865
652,adma biologics,4.1051990889813865
653,adma biologics,4.1051990889813865
654,adma biologics,4.1051990889813865
655,adma biologics,4.1051990889813865
656,adma biologics,4.1051990889813865
657,adma biologics,4.1051990889813865
658,adma biologics,4.1051990889813865
659,adma biologics,4.1051990889813865
660,adma biologics,4.1051990889813865
661,adma biologics,4.1051990889813865
662,adma biologics,4.1051990889813865
663,adma biologics,4.1051990889813865
664,adma biologics,4.1051990889813865
665,adma biologics,4.1051990889813865
666,fees,4.105177993527508
667,entities,4.104166666666667
668,loan documents,4.100502512562814
669,impairment charge,4.1
670,applicable notice,4.091666666666667
671,interim period,4.090796963946869
672,standardize ri,4.088235294117647
673,exercise price,4.08793324775353
674,sales,4.080952380952381
675,early adoption,4.0777777777777775
676,plasma,4.076190476190476
677,net cash,4.0744444444444445
678,exchange act,4.072398190045249
679,business combinations,4.072039072039072
680,adma,4.071590174531351
681,bank,4.071428571428571
682,approves,4.070680628272251
683,license agreement,4.0692326610919825
684,office building,4.066666666666666
685,applicable draw,4.066666666666666
686,higher costs,4.065148640101201
687,primarily related,4.064933417882054
688,commercial development,4.064212328767123
689,transaction price,4.063262195121951
690,collaborative agreements,4.0625
691,respective agreements,4.0625
692,development costs,4.059508027691854
693,deferred revenue,4.058947368421053
694,expenses,4.058081382132302
695,funded loan,4.057024251693249
696,significant impact,4.056051587301587
697,donors,4.055555555555555
698,donors,4.055555555555555
699,staff,4.055555555555555
700,regulatory developments,4.054545454545455
701,regulatory affairs,4.054545454545455
702,accounting principle,4.05
703,equity investments,4.046511627906977
704,manufacturing facility,4.044776119402985
705,financial statements,4.044604316546763
706,term,4.040201005025126
707,product manufacturer,4.038755980861244
708,contract manufacturing,4.0385806814981695
709,accounts payable,4.037162162162162
710,operating activities,4.036084529505582
711,performance obligations,4.030261969286359
712,transaction costs,4.026545698924731
713,making ri,4.025735294117647
714,firm commitments,4.020833333333334
715,warrants,4.020765027322405
716,regulatory activities,4.0204545454545455
717,antibodies,4.01978021978022
718,intellectual property,4.017857142857142
719,product development,4.015468309628368
720,license,4.0131578947368425
721,includes general,4.012121212121212
722,net sales,4.01095238095238
723,plasma,4.0095238095238095
724,lived assets,4.0060975609756095
725,annum equal,4.004081632653061
726,infectious diseases,4.0
727,medical reasons,4.0
728,korean ministry,4.0
729,collateral agent,4.0
730,technological innovations,4.0
731,key personnel,4.0
732,direct deduction,4.0
733,north africa,4.0
734,money judgments,4.0
735,collateral,4.0
736,underwriters,4.0
737,scholes methodology,4.0
738,regularly reviewed,4.0
739,support functions,4.0
740,finish provider,4.0
741,successfully resubmit,4.0
742,proper specifications,4.0
743,competitive developments,4.0
744,influenza type,4.0
745,genetic disorder,4.0
746,genetic defects,4.0
747,american academy,4.0
748,pk subjects,4.0
749,ordinarily leads,4.0
750,healthy adults,4.0
751,serum samples,4.0
752,samples,4.0
753,medical affairs,4.0
754,national distributors,4.0
755,fulfill orders,4.0
756,healthcare professionals,4.0
757,selected territories,4.0
758,remain consistent,4.0
759,attributableto,4.0
760,profitability,4.0
761,regions,4.0
762,greatly reduced,4.0
763,local governments,4.0
764,consumer spending,4.0
765,core principle,4.0
766,irrevocably opt,4.0
767,readily apparent,4.0
768,complex judgments,4.0
769,inherently uncertain,4.0
770,trading history,4.0
771,documentation,4.0
772,eighty percent,4.0
773,area,4.0
774,convergence,4.0
775,worked diligently,4.0
776,boca raton,4.0
777,vice chairman,4.0
778,pascack bankcorp,4.0
779,lakeland bancorp,4.0
780,biocenter,4.0
781,barrett parkway,4.0
782,eventually refiling,4.0
783,timely manner,4.0
784,inflation inflation,4.0
785,acute exposure,4.0
786,surface antigen,4.0
787,prenatal exposure,4.0
788,infants,4.0
789,positive mothers,4.0
790,sexual exposure,4.0
791,household exposure,4.0
792,highest priority,4.0
793,practical expedients,4.0
794,collectability criterion,4.0
795,location,4.0
796,net exercise,3.9984210526315787
797,standardized levels,3.9923076923076923
798,patients,3.989583333333333
799,earlier application,3.988530465949821
800,underwritten sale,3.984126984126984
801,amount,3.982300884955752
802,obligations,3.9814814814814814
803,deficiencies,3.9814814814814814
804,current cash,3.9801587301587302
805,activities,3.965909090909091
806,term manufacturing,3.965574139353484
807,minimal data,3.9655172413793105
808,information technology,3.9642857142857144
809,development programs,3.9600456621004567
810,legal fees,3.9593446601941746
811,periods,3.954688731284476
812,company,3.9533991228070176
813,debt financings,3.952675807164971
814,drug development,3.9517123287671234
815,additional details,3.951219512195122
816,additional indications,3.951219512195122
817,additional personnel,3.951219512195122
818,drug safety,3.95
819,table,3.95
820,table,3.95
821,expenses,3.947533929162529
822,warrant liability,3.947368421052632
823,line basis,3.9453441295546563
824,cash equivalents,3.9444444444444446
825,polyclonal antibodies,3.942857142857143
826,costs,3.9390982199331344
827,judgments,3.9375
828,adma,3.9369747899159666
829,adma,3.9369747899159666
830,related assets,3.936820452541875
831,revenues,3.9363636363636365
832,noncash charge,3.9333333333333336
833,cure period,3.929032258064516
834,notes,3.9245383997859244
835,term investments,3.9239219352576837
836,product revenue,3.917703349282297
837,goodwill,3.916666666666667
838,corporate collaboration,3.9144736842105265
839,risks,3.9130434782608696
840,numerous risks,3.9130434782608696
841,plans,3.9117647058823533
842,lessees,3.9117647058823533
843,financial instruments,3.911270983213429
844,fasb believes,3.9105180533751964
845,high levels,3.9102564102564106
846,significant dilution,3.90625
847,expected term,3.9050658698899907
848,ivig regularly,3.9047619047619047
849,enriched ivig,3.9047619047619047
850,marketing studies,3.904040404040404
851,full year,3.9002849002849
852,bacterial infections,3.9
853,senior management,3.897435897435898
854,biotest ag,3.8945099818511792
855,stock,3.8915338377343818
856,recorded related,3.889813800657174
857,substantive process,3.888888888888889
858,sg&amp,3.8888888888888884
859,received ri,3.8882352941176475
860,customary representations,3.887179487179487
861,amounts,3.8846153846153846
862,provisional amounts,3.8846153846153846
863,high dose,3.884615384615384
864,primarily consisted,3.8842105263157896
865,publicly update,3.883040935672515
866,single customer,3.8817733990147785
867,forego sales,3.880952380952381
868,sales,3.880952380952381
869,insurance charges,3.878787878787879
870,accrued expenses,3.8773584905660377
871,promotion expenses,3.8773584905660377
872,expenses,3.8773584905660377
873,development timelines,3.8767123287671232
874,oxford finance,3.876470588235294
875,product revenues,3.8751196172248803
876,accounts,3.875
877,safety profile,3.875
878,fees,3.8718446601941747
879,indebtedness,3.8695652173913047
880,timely basis,3.8684210526315788
881,material impact,3.868003341687552
882,potential evaluation,3.8639455782312924
883,contract fill,3.8632075471698113
884,middle east,3.857142857142857
885,restrictions,3.857142857142857
886,rsv survived,3.857142857142857
887,conduct,3.857142857142857
888,fda requested,3.856394913986537
889,legal proceedings,3.8541666666666665
890,compromised individuals,3.851851851851852
891,compromised populations,3.851851851851852
892,issues,3.8511904761904763
893,loan matures,3.850502512562814
894,licensing agreements,3.850378787878788
895,projected revenue,3.8503759398496245
896,values,3.85
897,disclosure requirements,3.846590909090909
898,approval,3.844490152081775
899,toxicology testing,3.84375
900,reduced testing,3.84375
901,dates,3.84375
902,filing fees,3.843273231622746
903,development activities,3.842621419676214
904,additional consideration,3.8401084010840107
905,fda issued,3.837347294938918
906,substantial completion,3.8373205741626792
907,current report,3.8357142857142854
908,fully transferable,3.833333333333333
909,efficacy endpoints,3.833333333333333
910,cash consideration,3.833333333333333
911,party vendors,3.8312020460358056
912,agreement,3.830268314742237
913,higher validation,3.829721362229102
914,cash expenses,3.8218029350104823
915,owned subsidiaries,3.821428571428571
916,investments,3.821220930232558
917,additional indebtedness,3.8207847295864266
918,implementation approach,3.8181818181818183
919,potential refinancing,3.816326530612245
920,including regulatory,3.810847975553858
921,assets,3.8087291399229786
922,potential timing,3.8064743138634767
923,aggregate number,3.8042857142857143
924,working capital,3.8016826923076925
925,necessarily indicative,3.8
926,underwriting discounts,3.8
927,proteins,3.8
928,received palivizumab,3.8
929,rsv antibodies,3.8
930,reasons,3.8
931,general warehousing,3.8
932,attestation report,3.8
933,final review,3.8
934,efficacy data,3.7988505747126435
935,loan maturity,3.7974722095325113
936,term liquidity,3.790201005025126
937,corporate priorities,3.7894736842105265
938,prepayment premiumand,3.788732394366197
939,prepayment penalty,3.788732394366197
940,voluntary prepayment,3.788732394366197
941,prepayment penalties,3.788732394366197
942,prepayment premium,3.788732394366197
943,commercial initiatives,3.7875
944,business units,3.786324786324786
945,business activity,3.786324786324786
946,business combination,3.786324786324786
947,period,3.7861751152073735
948,additional paid,3.784552845528455
949,estimated expenses,3.7836084905660377
950,potential risk,3.7806122448979593
951,revenue,3.7789473684210524
952,existing commitments,3.778409090909091
953,operational expenses,3.7773584905660376
954,proposed acquisition,3.7743506493506493
955,sales taxes,3.7698412698412698
956,biotest license,3.769736842105263
957,loan tranche,3.767169179229481
958,development process,3.765601217656012
959,process development,3.765601217656012
960,primary stockholders,3.7651515151515156
961,exchange commission,3.764705882352941
962,subsidiaries,3.762376237623762
963,lease term,3.7611312375832653
964,primarily held,3.7592105263157896
965,biotest aktiengesellschaft,3.7565789473684212
966,biotest evidenced,3.7565789473684212
967,limitations,3.7563025210084033
968,variances,3.7563025210084033
969,weissued warrants,3.7540983606557377
970,development expenses,3.754070819333161
971,consideration,3.7537537537537538
972,business activities,3.752233877233877
973,georgia facilities,3.752155172413793
974,related parties,3.7521514629948367
975,selected countries,3.75
976,historical experience,3.75
977,harbor provisions,3.75
978,risk groups,3.75
979,experience disruption,3.75
980,declining valuations,3.75
981,ten percent,3.75
982,guidance,3.7496884088076445
983,performance obligation,3.7487804878048783
984,000 previously paid,3.742424242424242
985,anticipated ri,3.738235294117647
986,amount,3.732300884955752
987,prepayment charge,3.7220657276995306
988,regulatory strategy,3.7212121212121216
989,high degree,3.717948717948718
990,date,3.7134502923976607
991,itsmaturity date,3.7134502923976607
992,quarterly report,3.709090909090909
993,initially recorded,3.709090909090909
994,recognize revenue,3.707518796992481
995,present fairly,3.7058823529411766
996,present separately,3.7058823529411766
997,interest,3.705769230769231
998,net loss,3.705
999,additional submission,3.701219512195122
1000,fda prior,3.700310257901881
1001,goods,3.7
1002,spot&quot,3.7
1003,products,3.6988795518207285
1004,amount,3.691391794046661
1005,time periods,3.6891822609587286
1006,marketing activities,3.688131313131313
1007,convertible debt,3.68796992481203
1008,begin repaying,3.685714285714286
1009,recognize assets,3.6846689895470384
1010,costs,3.682795698924731
1011,note payable,3.678291194420227
1012,january,3.673115079365079
1013,owned subsidiary,3.667582417582418
1014,derived therapeutics,3.666666666666667
1015,historical facts,3.666666666666667
1016,secondary outcome,3.666666666666667
1017,secondary outcomes,3.666666666666667
1018,wide range,3.666666666666667
1019,management,3.666666666666667
1020,management,3.666666666666667
1021,successfully close,3.666666666666667
1022,resources,3.6666666666666665
1023,information,3.666040100250626
1024,expansion activities,3.665909090909091
1025,remediation efforts,3.6634615384615383
1026,development business,3.6630371150919094
1027,completion costs,3.656479909451047
1028,funding date,3.653450292397661
1029,expenses,3.6515520389531346
1030,common stockholders,3.649695276790249
1031,patient populations,3.6470588235294117
1032,patient support,3.6470588235294117
1033,amounts,3.6454849498327757
1034,operating loss,3.6451754385964916
1035,term loans,3.640201005025126
1036,asu require,3.6395570828560517
1037,primarily attributable,3.6342105263157896
1038,key assumptions,3.6338028169014085
1039,quality testing,3.6332236842105265
1040,curtail activities,3.632575757575758
1041,assets,3.6310975609756095
1042,company,3.626315789473684
1043,written notice,3.625
1044,treatment centers,3.623809523809524
1045,period adjustments,3.6234767025089605
1046,recognize adjustments,3.623015873015873
1047,risks,3.621376811594203
1048,million commitment,3.6203796203796204
1049,date,3.6197002923976607
1050,monitor additional,3.617886178861789
1051,immediately precedes,3.6153846153846154
1052,differ materially,3.6153846153846154
1053,completed prior,3.6149237472766886
1054,contingent assets,3.613240418118467
1055,footnote disclosures,3.6126126126126126
1056,pathogen antibodies,3.6095238095238096
1057,current guidance,3.6046798029556646
1058,analyze performance,3.6043360433604335
1059,adma,3.603641456582633
1060,loan amendment,3.600502512562814
1061,biotest transaction,3.6003289473684212
1062,quot,3.6
1063,date,3.5976608187134502
1064,conditions,3.596273291925466
1065,year,3.5925925925925926
1066,calendar year,3.5925925925925926
1067,calendar,3.5925925925925926
1068,market,3.588235294117647
1069,negatively impact,3.587301587301587
1070,prior lender,3.5841750841750843
1071,future milestones,3.5794085432639653
1072,date,3.5783151572625256
1073,purchase price,3.575444398511782
1074,statements,3.574193548387097
1075,contracting parties,3.571428571428571
1076,fda request,3.5706806282722514
1077,significant volatility,3.56875
1078,operational management,3.5666666666666664
1079,data,3.56551724137931
1080,principal stockholder,3.56140350877193
1081,materially affect,3.56
1082,commercialization activities,3.552865612648221
1083,claims,3.5454545454545454
1084,insurance premiums,3.5454545454545454
1085,assumptions,3.5428937259923177
1086,prepayment,3.538732394366197
1087,remediation plans,3.5367647058823533
1088,employee share,3.5357142857142856
1089,current conclusions,3.5357142857142856
1090,continuing implementation,3.5324675324675323
1091,debts,3.5272727272727273
1092,school,3.5272727272727273
1093,hospitalization,3.5272727272727273
1094,reimbursement levels,3.5256410256410255
1095,year period,3.5216248506571084
1096,special note,3.5161290322580645
1097,current lsa,3.515389082462253
1098,line item,3.514423076923077
1099,biotest assets,3.512676508344031
1100,extension term,3.5107892403192436
1101,leases existing,3.507575757575758
1102,statements,3.5017543859649125
1103,substantially attributable,3.5
1104,market size,3.5
1105,market acceptance,3.5
1106,varying interpretations,3.5
1107,successfully develop,3.5
1108,greater rise,3.5
1109,acquirer record,3.5
1110,positive persons,3.5
1111,fda resubmission,3.4937575513491748
1112,significantly delay,3.493548387096774
1113,acquisition transaction,3.4931006493506493
1114,approved facilities,3.491071428571429
1115,pidd population,3.489795918367347
1116,patients,3.489583333333333
1117,infected patients,3.489583333333333
1118,treated patients,3.489583333333333
1119,declared effective,3.4875
1120,successfully completed,3.485294117647059
1121,actual results,3.4828982898289826
1122,proposed treatment,3.482142857142857
1123,updated standard,3.4814814814814814
1124,standard introduces,3.4814814814814814
1125,guidance,3.4807302231237323
1126,expenses,3.4773584905660377
1127,expenses,3.4773584905660377
1128,oxford loan,3.476973100798108
1129,unattractive terms,3.4743589743589745
1130,contractual terms,3.4743589743589745
1131,favorable terms,3.4743589743589745
1132,completion,3.473684210526316
1133,party customers,3.4705882352941178
1134,operating expenditures,3.4701754385964914
1135,current stockholders,3.4675324675324672
1136,limitations,3.466666666666667
1137,adma,3.4632905793896507
1138,amendments,3.462121212121212
1139,credit availability,3.460526315789474
1140,timing related,3.4565849605317824
1141,warrants,3.45585274662065
1142,business strategy,3.452991452991453
1143,change,3.449654671028717
1144,perform interim,3.447478991596639
1145,patent protection,3.447368421052632
1146,effectively identify,3.4444444444444446
1147,solutions,3.4444444444444446
1148,sufficient cash,3.4444444444444446
1149,disclosure thresholds,3.4375
1150,overhead comprised,3.433333333333333
1151,period,3.429032258064516
1152,approved globally,3.428571428571429
1153,step approach,3.428571428571429
1154,adma,3.4222689075630255
1155,operating results,3.4167100920618383
1156,conducted prior,3.4153439153439153
1157,uncertainties,3.413793103448276
1158,purchase agreement,3.4120069697449704
1159,distribution plans,3.4117647058823533
1160,classified statement,3.411111111111111
1161,income statement,3.411111111111111
1162,maturity date,3.410419989367358
1163,option activity,3.4054054054054053
1164,activities,3.403409090909091
1165,infections,3.4
1166,grossman,3.4
1167,grossman family,3.4
1168,adoption,3.3896358543417366
1169,implementation guidance,3.3871473354231973
1170,governmental regulations,3.3846153846153846
1171,acceptable terms,3.3834498834498836
1172,immune deficiencies,3.3667273831208258
1173,compliance issues,3.365079365079365
1174,evaluate ri,3.3640973630831645
1175,acquisition date,3.3628009417483105
1176,liabilities,3.3605870020964357
1177,company,3.3596491228070176
1178,company,3.3596491228070176
1179,company,3.3596491228070176
1180,company prepays,3.3596491228070176
1181,company,3.3596491228070176
1182,default,3.357142857142857
1183,month interest,3.355769230769231
1184,income taxes,3.355555555555555
1185,fair values,3.3553191489361702
1186,recognized totaled $2,3.351063829787234
1187,recognized totaled $1,3.351063829787234
1188,rsv patients,3.3467261904761907
1189,historical results,3.346534653465347
1190,face amount,3.345937248592116
1191,measurement period,3.345698924731183
1192,partially offset,3.344827586206897
1193,compromised patients,3.341435185185185
1194,consisting primarily,3.338755980861244
1195,reportable segments,3.333333333333333
1196,historical fact,3.333333333333333
1197,asthma,3.333333333333333
1198,fairness opinion,3.333333333333333
1199,terms,3.3315018315018317
1200,adjustment,3.3221153846153846
1201,goodwill,3.3166666666666664
1202,comparable amount,3.3156342182890857
1203,complications,3.3076923076923075
1204,virus infection,3.3055555555555554
1205,subsequently expensed,3.287449392712551
1206,operations,3.2867647058823533
1207,therapeutics research,3.2857142857142856
1208,fda identified,3.2790139616055844
1209,current estimates,3.2785714285714285
1210,share amounts,3.2774725274725274
1211,adversely affect,3.274285714285714
1212,technical corrections,3.2727272727272725
1213,current expectations,3.2710084033613445
1214,bpc,3.269230769230769
1215,prepayment,3.2687323943661974
1216,marketing efforts,3.2606837606837606
1217,approximates fair,3.25531914893617
1218,time points,3.253012048192771
1219,time consuming,3.253012048192771
1220,time frame,3.253012048192771
1221,time horizon,3.253012048192771
1222,606 defines,3.25
1223,limited revenue,3.24953560371517
1224,company,3.2485380116959064
1225,market conditions,3.2391304347826084
1226,business day,3.230769230769231
1227,offset primarily,3.2290381125226864
1228,entity satisfies,3.2241379310344827
1229,current portion,3.2175324675324672
1230,staffing,3.2142857142857144
1231,uncertainties,3.2137931034482756
1232,quality assurance,3.2105263157894735
1233,continued duration,3.207792207792208
1234,treated approximately,3.203883495145631
1235,additional post,3.201219512195122
1236,effective date,3.200950292397661
1237,terms,3.195289206917114
1238,previously conducted,3.1948051948051948
1239,company,3.192982456140351
1240,deficiencies,3.189814814814815
1241,uncertainties,3.1879866518353728
1242,circumstances,3.1875
1243,customer,3.185344827586207
1244,read carefully,3.1818181818181817
1245,hepatitis,3.1764705882352944
1246,summary table,3.175806451612903
1247,summary table,3.175806451612903
1248,fund adma,3.1703081232493
1249,order,3.166666666666667
1250,estimated fair,3.16156914893617
1251,company,3.159649122807018
1252,entity,3.152709359605911
1253,business plan,3.14996114996115
1254,million loan,3.1494535615138632
1255,amended lsa,3.1463414634146343
1256,covenants,3.142857142857143
1257,grants,3.140917905623788
1258,expected timing,3.1407269338303823
1259,guidance,3.1396461455136304
1260,change,3.130952380952381
1261,oxford warrants,3.1305689488910318
1262,measurement date,3.1301169590643276
1263,management,3.128205128205128
1264,lower validation,3.1259398496240602
1265,commercialization efforts,3.125418060200669
1266,marked increase,3.125
1267,connection,3.1219512195121952
1268,company,3.1205186880244087
1269,year warrant,3.1189083820662766
1270,month basis,3.1184210526315788
1271,002 patent,3.1140350877192984
1272,company,3.1096491228070176
1273,additional shares,3.103118246372337
1274,thefirst anniversary,3.096774193548387
1275,bla resubmission,3.0959164292497627
1276,general operations,3.086764705882353
1277,transfer ownership,3.083333333333333
1278,months,3.0760233918128654
1279,business operations,3.0730894922071395
1280,company,3.0687400318979265
1281,company,3.0687400318979265
1282,rsv form,3.0515873015873014
1283,asia,3.0508474576271185
1284,income effects,3.05
1285,entity,3.0455665024630543
1286,dated december,3.042553191489362
1287,dated december,3.042553191489362
1288,20 years,3.02997045166737
1289,company,3.026315789473684
1290,bpc assets,3.0253283302063787
1291,forward period,3.0199413489736067
1292,closing date,3.0190058479532165
1293,fda accepted,3.015125072716696
1294,exclusive manufacture,3.008928571428571
1295,safety,2.9926470588235294
1296,pidd patients,2.9793792517006805
1297,btbu,2.9743589743589745
1298,amortization date,2.9634502923976607
1299,amortization date,2.9634502923976607
1300,effective prospectively,2.9611842105263158
1301,licensed products,2.9607843137254903
1302,company,2.9596491228070176
1303,company director,2.931077694235589
1304,loss,2.9260638297872337
1305,company,2.885964912280702
1306,company,2.885964912280702
1307,fold increase,2.875
1308,collect approximately 30,2.8705501618122975
1309,company,2.8596491228070176
1310,risk factors,2.85
1311,company,2.8449432404540764
1312,secured obligation,2.8428571428571425
1313,applied prospectively,2.8421052631578947
1314,assumptions,2.8338028169014082
1315,comparable terminology,2.833333333333333
1316,assumptions,2.8282472613458527
1317,adoption,2.8268817204301078
1318,company,2.826315789473684
1319,duration,2.79020979020979
1320,market research,2.7857142857142856
1321,company,2.776315789473684
1322,estimates,2.769172932330827
1323,implied fair,2.75531914893617
1324,company,2.7406015037593985
1325,market nabi,2.7333333333333334
1326,internal control,2.7333333333333334
1327,share computation,2.7261904761904763
1328,outstanding,2.711864406779661
1329,collection,2.696969696969697
1330,concern uncertainties,2.6804597701149424
1331,defined terms,2.6743589743589746
1332,inventory,2.654166666666667
1333,concern assessment,2.651282051282051
1334,customer,2.6436781609195403
1335,increased,2.642857142857143
1336,title transfers,2.635294117647059
1337,supplies,2.6153846153846154
1338,public,2.6031746031746033
1339,completed contracts,2.6029411764705883
1340,extended,2.6
1341,beginning,2.59375
1342,commencement,2.5555555555555554
1343,letter,2.5454545454545454
1344,annual,2.5416666666666665
1345,transition,2.5416666666666665
1346,company,2.5414673046251997
1347,granted,2.53125
1348,potential,2.5306122448979593
1349,scope improvements,2.5274725274725274
1350,fund operations,2.5200980392156866
1351,purchase shares,2.5078309375670456
1352,obtain,2.4782608695652173
1353,plasma,2.4761904761904763
1354,approximately half,2.4705501618122976
1355,applicable,2.466666666666667
1356,revised,2.4545454545454546
1357,fasb,2.4489795918367347
1358,offering,2.4468085106382977
1359,clinical,2.4444444444444446
1360,arrangements,2.433333333333333
1361,biotechnology,2.4285714285714284
1362,average,2.4285714285714284
1363,response,2.4285714285714284
1364,production,2.4
1365,future,2.397590361445783
1366,total,2.389830508474576
1367,supply,2.3846153846153846
1368,payment,2.3617021276595747
1369,commercialize,2.357142857142857
1370,party,2.3529411764705883
1371,companies,2.347826086956522
1372,rate,2.3333333333333335
1373,approvals,2.3333333333333335
1374,physicians,2.3333333333333335
1375,preclinical,2.3333333333333335
1376,administrative,2.3333333333333335
1377,measured,2.3333333333333335
1378,options,2.3333333333333335
1379,human,2.317073170731707
1380,7 million comprised,2.315617715617716
1381,application,2.311111111111111
1382,approval,2.2738095238095237
1383,002 approval,2.2738095238095237
1384,fees,2.2718446601941746
1385,diluted,2.2666666666666666
1386,issued,2.2666666666666666
1387,normal,2.264705882352941
1388,exercisable,2.25
1389,negative,2.25
1390,transactions,2.25
1391,financial,2.2446043165467624
1392,dilutive,2.238095238095238
1393,principal,2.2280701754385963
1394,position,2.227272727272727
1395,financing,2.2162162162162162
1396,includes,2.212121212121212
1397,credit,2.210526315789474
1398,equal,2.204081632653061
1399,borrowed,2.2
1400,modification,2.2
1401,securities,2.1956521739130435
1402,levels,2.1923076923076925
1403,debt,2.18796992481203
1404,costs,2.182795698924731
1405,balances,2.1818181818181817
1406,test,2.1818181818181817
1407,studies,2.1818181818181817
1408,related,2.180722891566265
1409,781 related,2.180722891566265
1410,experienced,2.1666666666666665
1411,immunodeficiency,2.1666666666666665
1412,overhead,2.1666666666666665
1413,certified,2.1666666666666665
1414,impairment,2.1666666666666665
1415,equity,2.1627906976744184
1416,interim,2.161764705882353
1417,lead,2.142857142857143
1418,issues,2.142857142857143
1419,quantities,2.142857142857143
1420,overview,2.142857142857143
1421,employee,2.142857142857143
1422,cease,2.142857142857143
1423,product,2.138755980861244
1424,stock,2.1352313167259784
1425,provided,2.1346153846153846
1426,net,2.13
1427,prior,2.1296296296296298
1428,002 prior,2.1296296296296298
1429,facility,2.1194029850746268
1430,contract,2.1132075471698113
1431,depending,2.111111111111111
1432,subjective,2.111111111111111
1433,capital,2.109375
1434,trial,2.107142857142857
1435,interest,2.105769230769231
1436,forfeitures,2.1052631578947367
1437,percentage,2.103448275862069
1438,loan,2.100502512562814
1439,receiving,2.090909090909091
1440,drug,2.075
1441,services,2.0714285714285716
1442,bank,2.0714285714285716
1443,based,2.068702290076336
1444,office,2.066666666666667
1445,facilities,2.0625
1446,agreements,2.0625
1447,agreement,2.05607476635514
1448,virus,2.0555555555555554
1449,regulatory,2.0545454545454547
1450,acquired,2.0526315789473686
1451,accounting,2.05
1452,term,2.040201005025126
1453,current,2.0357142857142856
1454,expense,2.028169014084507
1455,license,2.013157894736842
1456,method,2.0
1457,prevent,2.0
1458,treated,2.0
1459,type,2.0
1460,consist,2.0
1461,earnings,2.0
1462,standards,2.0
1463,operated,2.0
1464,undertaken,2.0
1465,amount,1.9823008849557522
1466,obligations,1.9814814814814814
1467,activities,1.9659090909090908
1468,data,1.9655172413793103
1469,information,1.9642857142857142
1470,number,1.9642857142857142
1471,funded,1.9565217391304348
1472,additional,1.951219512195122
1473,additional $4,1.951219512195122
1474,additional $5,1.951219512195122
1475,additional $20,1.951219512195122
1476,additional $12,1.951219512195122
1477,additional $969,1.951219512195122
1478,patent,1.9473684210526316
1479,validation,1.9473684210526316
1480,patent,1.9473684210526316
1481,disclosures,1.945945945945946
1482,cash,1.9444444444444444
1483,statement,1.9444444444444444
1484,antibodies,1.9428571428571428
1485,funding,1.94
1486,adma,1.9369747899159664
1487,funds,1.9333333333333333
1488,period,1.929032258064516
1489,planning,1.9285714285714286
1490,recognize,1.9285714285714286
1491,manufacturing,1.9253731343283582
1492,resubmission,1.9230769230769231
1493,goodwill,1.9166666666666667
1494,risks,1.9130434782608696
1495,requires,1.911764705882353
1496,underlying,1.9090909090909092
1497,grant,1.90625
1498,estimated,1.90625
1499,ivig,1.9047619047619047
1500,manufacturer,1.9
1501,issue,1.8888888888888888
1502,igg,1.8888888888888888
1503,process,1.8888888888888888
1504,retrospective,1.8888888888888888
1505,taxes,1.8888888888888888
1506,assumed,1.8888888888888888
1507,immune,1.8852459016393444
1508,amounts,1.8846153846153846
1509,primarily,1.8842105263157896
1510,investments,1.8837209302325582
1511,higher,1.8823529411764706
1512,sales,1.880952380952381
1513,expenses,1.8773584905660377
1514,development,1.8767123287671232
1515,accounts,1.875
1516,property,1.875
1517,safety,1.875
1518,indebtedness,1.8695652173913044
1519,exercise,1.868421052631579
1520,basis,1.868421052631579
1521,expected,1.864864864864865
1522,rsv,1.8571428571428572
1523,vesting,1.8571428571428572
1524,middle,1.8571428571428572
1525,compromised,1.8518518518518519
1526,subsidiary,1.8461538461538463
1527,testing,1.84375
1528,transaction,1.84375
1529,aggregate,1.84
1530,paid,1.8333333333333333
1531,000 paid,1.8333333333333333
1532,efficacy,1.8333333333333333
1533,7 years,1.826086956521739
1534,1 years,1.826086956521739
1535,years,1.826086956521739
1536,0 years,1.826086956521739
1537,5 years,1.826086956521739
1538,10 years,1.826086956521739
1539,6 years,1.826086956521739
1540,3 years,1.826086956521739
1541,asu,1.824742268041237
1542,owned,1.8214285714285714
1543,implementation,1.8181818181818181
1544,require,1.8148148148148149
1545,report,1.8
1546,statements,1.8
1547,necessarily,1.8
1548,received,1.8
1549,general,1.8
1550,generated,1.8
1551,000 received,1.8
1552,annum,1.8
1553,stated,1.8
1554,discounts,1.8
1555,products,1.7941176470588236
1556,corporate,1.7894736842105263
1557,quality,1.7894736842105263
1558,prepayment,1.7887323943661972
1559,licensing,1.7878787878787878
1560,business,1.7863247863247864
1561,revenue,1.7789473684210526
1562,events,1.7777777777777777
1563,hiring,1.7777777777777777
1564,permitted,1.775
1565,include,1.7741935483870968
1566,exchange,1.7647058823529411
1567,financings,1.7647058823529411
1568,notes,1.7623762376237624
1569,reported,1.7608695652173914
1570,biotest,1.756578947368421
1571,including,1.7563025210084033
1572,assets,1.7560975609756098
1573,warrants,1.7540983606557377
1574,made,1.75
1575,carrying,1.75
1576,9 fold,1.75
1577,3 fold,1.75
1578,fold,1.75
1579,experience,1.75
1580,attributable,1.75
1581,097 attributable,1.75
1582,liquidity,1.75
1583,countries,1.75
1584,provisions,1.75
1585,substantially,1.75
1586,fill,1.75
1587,conditions,1.7391304347826086
1588,revenues,1.7363636363636363
1589,representations,1.7333333333333334
1590,2015 consists,1.7272727272727273
1591,consists,1.7272727272727273
1592,blood,1.7272727272727273
1593,marketing,1.7222222222222223
1594,lease,1.7209302325581395
1595,high,1.7179487179487178
1596,input,1.7142857142857142
1597,adversely,1.7142857142857142
1598,continuing,1.7142857142857142
1599,date,1.713450292397661
1600,recorded,1.709090909090909
1601,recorded $367,1.709090909090909
1602,identified,1.7083333333333333
1603,present,1.7058823529411764
1604,llc,1.7058823529411764
1605,included,1.7017543859649122
1606,expansion,1.7
1607,obligation,1.7
1608,goods,1.7
1609,maturity,1.696969696969697
1610,inventories,1.6956521739130435
1611,adjustments,1.6944444444444444
1612,working,1.6923076923076923
1613,methods,1.6923076923076923
1614,georgia,1.6896551724137931
1615,commitments,1.6875
1616,legal,1.6875
1617,effect,1.6857142857142857
1618,earlier,1.6774193548387097
1619,amended,1.6666666666666667
1620,management,1.6666666666666667
1621,anti,1.6666666666666667
1622,tranche,1.6666666666666667
1623,purposes,1.6666666666666667
1624,derived,1.6666666666666667
1625,strategy,1.6666666666666667
1626,outcomes,1.6666666666666667
1627,meeting,1.6666666666666667
1628,pathogen,1.6666666666666667
1629,baseline,1.6666666666666667
1630,segment,1.6666666666666667
1631,critical,1.6666666666666667
1632,footnote 3,1.6666666666666667
1633,outcome,1.6666666666666667
1634,range,1.6666666666666667
1635,assist,1.6666666666666667
1636,collect,1.6666666666666667
1637,secure,1.6666666666666667
1638,participate,1.6666666666666667
1639,chargebacks,1.6666666666666667
1640,anticipated,1.65
1641,acquisition,1.6493506493506493
1642,patient,1.6470588235294117
1643,storage,1.6428571428571428
1644,selling,1.6363636363636365
1645,duration,1.6363636363636365
1646,assumptions,1.6338028169014085
1647,adoption,1.6333333333333333
1648,pursuant,1.631578947368421
1649,notice,1.625
1650,differ,1.6153846153846154
1651,apply,1.6153846153846154
1652,immediately,1.6153846153846154
1653,valuation,1.6
1654,draw,1.6
1655,factors,1.6
1656,obtained,1.6
1657,incurred,1.6
1658,loans,1.6
1659,therapy,1.6
1660,initiatives,1.6
1661,year,1.5925925925925926
1662,sell,1.588235294117647
1663,impact,1.5873015873015872
1664,commercialization,1.5869565217391304
1665,effects,1.5833333333333333
1666,loss,1.575
1667,filing,1.5714285714285714
1668,parties,1.5714285714285714
1669,exclusive,1.5714285714285714
1670,continued,1.5714285714285714
1671,director,1.5714285714285714
1672,fda,1.5706806282722514
1673,guidance,1.5689655172413792
1674,rent,1.565217391304348
1675,affect,1.56
1676,classification,1.56
1677,analyze,1.5555555555555556
1678,claims,1.5454545454545454
1679,insurance,1.5454545454545454
1680,efforts,1.5384615384615385
1681,intended,1.5333333333333334
1682,presentation,1.5333333333333334
1683,due,1.5272727272727273
1684,002 due,1.5272727272727273
1685,entered,1.5263157894736843
1686,warrant,1.5263157894736843
1687,make,1.5263157894736843
1688,adopted,1.5263157894736843
1689,presented,1.5185185185185186
1690,note 3,1.5161290322580645
1691,note 8,1.5161290322580645
1692,cost,1.5161290322580645
1693,note 4,1.5161290322580645
1694,note,1.5161290322580645
1695,mfds,1.5
1696,2016 amendment,1.5
1697,sufficient,1.5
1698,convertible,1.5
1699,protection,1.5
1700,market,1.5
1701,asset,1.5
1702,greater,1.5
1703,reimburses,1.5
1704,accessing,1.5
1705,terminology,1.5
1706,implied,1.5
1707,develop,1.5
1708,conclusions,1.5
1709,placebo,1.5
1710,spot,1.5
1711,acquirer,1.5
1712,allocate,1.5
1713,amendment,1.5
1714,round,1.5
1715,submissions,1.5
1716,managing,1.5
1717,98%,1.5
1718,commencing,1.5
1719,persons,1.5
1720,lives,1.5
1721,interpretations,1.5
1722,pidd,1.489795918367347
1723,patients,1.4895833333333333
1724,59 patients,1.4895833333333333
1725,21 patients,1.4895833333333333
1726,13 patients,1.4895833333333333
1727,15 patients,1.4895833333333333
1728,11 patients,1.4895833333333333
1729,effective,1.4875
1730,completed,1.4852941176470589
1731,deficiencies,1.4814814814814814
1732,standard,1.4814814814814814
1733,occurs,1.48
1734,lsa,1.4796747967479675
1735,vendors,1.4782608695652173
1736,terms,1.4743589743589745
1737,prospectively,1.4736842105263157
1738,completion,1.4736842105263157
1739,liabilities,1.471698113207547
1740,limited,1.4705882352941178
1741,extension,1.4705882352941178
1742,income,1.4666666666666666
1743,classified,1.4666666666666666
1744,measure,1.4666666666666666
1745,agreed,1.4666666666666666
1746,believes,1.4615384615384615
1747,lender,1.4545454545454546
1748,consisting,1.4545454545454546
1749,accepted,1.4444444444444444
1750,modified,1.4444444444444444
1751,developing,1.4444444444444444
1752,12 months,1.4444444444444444
1753,day,1.4444444444444444
1754,identify,1.4444444444444444
1755,36 months,1.4444444444444444
1756,months,1.4444444444444444
1757,day,1.4444444444444444
1758,24 months,1.4444444444444444
1759,end,1.4390243902439024
1760,item,1.4375
1761,manufacture,1.4375
1762,dilution,1.4375
1763,disclosure,1.4375
1764,15 item,1.4375
1765,launch,1.4375
1766,adjustment,1.4375
1767,stockholders,1.4318181818181819
1768,approved,1.4285714285714286
1769,represents,1.4285714285714286
1770,step,1.4285714285714286
1771,step,1.4285714285714286
1772,assurance,1.4210526315789473
1773,leases,1.4166666666666667
1774,measurement,1.4166666666666667
1775,uncertainties,1.4137931034482758
1776,plans,1.411764705882353
1777,option,1.4054054054054055
1778,expenditures,1.4
1779,allowance,1.4
1780,accelerated,1.4
1781,transfers,1.4
1782,column,1.4
1783,infections,1.4
1784,open,1.4
1785,control,1.4
1786,reasonable,1.4
1787,acquire,1.4
1788,grossman,1.4
1789,allocated,1.4
1790,share,1.3928571428571428
1791,operates,1.3846153846153846
1792,grants,1.3846153846153846
1793,regulations,1.3846153846153846
1794,improvements,1.3846153846153846
1795,assessment,1.3846153846153846
1796,change,1.380952380952381
1797,oxford,1.3764705882352941
1798,benefits,1.3703703703703705
1799,applied,1.368421052631579
1800,2007 plan,1.3636363636363635
1801,2014 plan,1.3636363636363635
1802,plan,1.3636363636363635
1803,face,1.3636363636363635
1804,company,1.3596491228070176
1805,treatment,1.3571428571428572
1806,default,1.3571428571428572
1807,pre,1.3571428571428572
1808,purchase 74,1.3559322033898304
1809,purchase,1.3559322033898304
1810,purchase 15,1.3559322033898304
1811,purchase,1.3559322033898304
1812,purchase 24,1.3559322033898304
1813,recognized,1.351063829787234
1814,gaap,1.3478260869565217
1815,results,1.3465346534653466
1816,offset,1.3448275862068966
1817,2016 offset,1.3448275862068966
1818,002 offset,1.3448275862068966
1819,opinion,1.3333333333333333
1820,internal,1.3333333333333333
1821,computation,1.3333333333333333
1822,insolvency,1.3333333333333333
1823,liquidation,1.3333333333333333
1824,stockholder,1.3333333333333333
1825,segments,1.3333333333333333
1826,issuance,1.3333333333333333
1827,anticipates,1.3333333333333333
1828,nature,1.3333333333333333
1829,evaluation,1.3333333333333333
1830,comparable,1.3333333333333333
1831,fact,1.3333333333333333
1832,reimbursement,1.3333333333333333
1833,instability,1.3333333333333333
1834,accounted,1.3333333333333333
1835,minimum,1.3333333333333333
1836,restated,1.3333333333333333
1837,&amp,1.3333333333333333
1838,deficit,1.3333333333333333
1839,preliminary,1.3333333333333333
1840,life,1.3333333333333333
1841,package,1.3333333333333333
1842,iii,1.32
1843,customer,1.3103448275862069
1844,suffer,1.3076923076923077
1845,occur,1.3076923076923077
1846,btbu,1.3076923076923077
1847,closing,1.3055555555555556
1848,operations,1.286764705882353
1849,hercules,1.2857142857142858
1850,conducted,1.2857142857142858
1851,research,1.2857142857142858
1852,begin,1.2857142857142858
1853,refinancing,1.2857142857142858
1854,perform,1.2857142857142858
1855,timing,1.2758620689655173
1856,evaluate,1.2758620689655173
1857,corrections,1.2727272727272727
1858,bpc,1.2692307692307692
1859,half,1.2666666666666666
1860,comprised,1.2666666666666666
1861,awards,1.2666666666666666
1862,concern,1.2666666666666666
1863,reduce,1.2608695652173914
1864,fair,1.2553191489361701
1865,time,1.2530120481927711
1866,availability,1.25
1867,risk,1.25
1868,month,1.25
1869,infection,1.25
1870,amortization,1.25
1871,rights,1.25
1872,amendments,1.25
1873,post,1.25
1874,intermediate,1.25
1875,asc 718,1.25
1876,asc 606,1.25
1877,reflects,1.25
1878,estimates,1.2428571428571429
1879,title,1.2352941176470589
1880,expectations,1.2352941176470589
1881,fund,1.2333333333333334
1882,nabi,1.2333333333333334
1883,provide,1.2307692307692308
1884,summary,1.2258064516129032
1885,entity,1.2241379310344827
1886,compliance,1.2222222222222223
1887,expire,1.2222222222222223
1888,anticipate,1.2142857142857142
1889,expensed,1.2105263157894737
1890,subject,1.205128205128205
1891,approximately $29,1.203883495145631
1892,approximately $11,1.203883495145631
1893,approximately $15,1.203883495145631
1894,approximately $0,1.203883495145631
1895,approximately $14,1.203883495145631
1896,approximately $10,1.203883495145631
1897,approximately $1,1.203883495145631
1898,approximately 2,1.203883495145631
1899,approximately $13,1.203883495145631
1900,approximately $4,1.203883495145631
1901,approximately $12,1.203883495145631
1902,approximately $26,1.203883495145631
1903,5%,1.203883495145631
1904,approximately 12,1.203883495145631
1905,approximately,1.203883495145631
1906,approximately $20,1.203883495145631
1907,approximately $500,1.203883495145631
1908,required,1.2
1909,carried,1.2
1910,defined,1.2
1911,investment,1.2
1912,depreciation,1.2
1913,signed,1.2
1914,form 10,1.1944444444444444
1915,form,1.1944444444444444
1916,form,1.1944444444444444
1917,delay,1.1935483870967742
1918,employees,1.1935483870967742
1919,inventory,1.1875
1920,circumstances,1.1875
1921,intends,1.1818181818181819
1922,portion,1.1818181818181819
1923,read,1.1818181818181819
1924,prepared,1.1818181818181819
1925,milestones,1.1818181818181819
1926,lower,1.1785714285714286
1927,hepatitis,1.1764705882352942
1928,bla,1.1728395061728396
1929,equipment,1.1724137931034482
1930,review,1.1666666666666667
1931,filed,1.1666666666666667
1932,engaged,1.1666666666666667
1933,licensed,1.1666666666666667
1934,order,1.1666666666666667
1935,seller,1.1666666666666667
1936,10 days,1.1538461538461537
1937,90 days,1.1538461538461537
1938,93 days,1.1538461538461537
1939,66 days,1.1538461538461537
1940,2 days,1.1538461538461537
1941,shares,1.1518987341772151
1942,000 shares,1.1518987341772151
1943,309 shares,1.1518987341772151
1944,154 shares,1.1518987341772151
1945,984 shares,1.1518987341772151
1946,800 shares,1.1518987341772151
1947,580 shares,1.1518987341772151
1948,160 shares,1.1518987341772151
1949,completing,1.1428571428571428
1950,covenants,1.1428571428571428
1951,scope,1.1428571428571428
1952,remaining $5,1.1428571428571428
1953,secured,1.1428571428571428
1954,incorrect,1.1428571428571428
1955,areth,1.1428571428571428
1956,repay,1.1333333333333333
1957,august,1.125
1958,increase,1.125
1959,manufactured,1.125
1960,resulting,1.125
1961,august 2014,1.125
1962,connection,1.1219512195121952
1963,food,1.1176470588235294
1964,meet,1.1176470588235294
1965,contracts,1.1176470588235294
1966,customers,1.1176470588235294
1967,submitted,1.1111111111111112
1968,matters,1.1111111111111112
1969,002 submitted,1.1111111111111112
1970,infusion,1.1111111111111112
1971,wholly,1.105263157894737
1972,update,1.105263157894737
1973,volatility,1.1
1974,event,1.096774193548387
1975,anniversary,1.096774193548387
1976,sale,1.0952380952380953
1977,extent,1.0909090909090908
1978,forward,1.0909090909090908
1979,expects,1.0833333333333333
1980,transfer,1.0833333333333333
1981,january 31,1.0793650793650793
1982,january 1,1.0793650793650793
1983,january 2016,1.0793650793650793
1984,january 2035,1.0793650793650793
1985,january 21,1.0793650793650793
1986,january 2017,1.0793650793650793
1987,short,1.0714285714285714
1988,bivigam,1.0666666666666667
1989,determined,1.0555555555555556
1990,july,1.0555555555555556
1991,july,1.0555555555555556
1992,continue,1.0508474576271187
1993,1 million,1.048951048951049
1994,3 million,1.048951048951049
1995,0 million,1.048951048951049
1996,7 million,1.048951048951049
1997,4 million,1.048951048951049
1998,9 million,1.048951048951049
1999,5 million,1.048951048951049
2000,8 million,1.048951048951049
2001,2 million,1.048951048951049
2002,6 million,1.048951048951049
2003,decrease,1.0454545454545454
2004,december,1.0425531914893618
2005,december,1.0425531914893618
2006,december,1.0425531914893618
2007,december,1.0425531914893618
2008,december,1.0425531914893618
2009,wages,1.0416666666666667
2010,september,1.0416666666666667
2011,september 30,1.0416666666666667
2012,shipment,1.0384615384615385
2013,march 2015,1.0212765957446808
2014,march 31,1.0212765957446808
2015,march,1.0212765957446808
2016,march 18,1.0212765957446808
2017,march,1.0212765957446808
2018,crl,1.0175438596491229
2019,unaudited,1.0
2020,deficiency,1.0
2021,organization,1.0
2022,develops,1.0
2023,manufactures,1.0
2024,prevention,1.0
2025,suppressed,1.0
2026,norcross,1.0
2027,marietta,1.0
2028,gha,1.0
2029,quarter,1.0
2030,inception,1.0
2031,october,1.0
2032,ipo,1.0
2033,june,1.0
2034,february 24,1.0
2035,elect,1.0
2036,extend,1.0
2037,predicated,1.0
2038,brings,1.0
2039,expect,1.0
2040,borrow,1.0
2041,result,1.0
2042,incurrence,1.0
2043,restrict,1.0
2044,eliminate,1.0
2045,june,1.0
2046,long,1.0
2047,dependent,1.0
2048,ability,1.0
2049,dependence,1.0
2050,competitors,1.0
2051,principles,1.0
2052,consolidation,1.0
2053,eliminated,1.0
2054,conjunction,1.0
2055,sec,1.0
2056,accordance,1.0
2057,america,1.0
2058,rules,1.0
2059,condensed,1.0
2060,omitted,1.0
2061,resale,1.0
2062,inthecompany,1.0
2063,sresearch,1.0
2064,processed,1.0
2065,april,1.0
2066,imputation,1.0
2067,recast,1.0
2068,conform,1.0
2069,delivery,1.0
2070,europe,1.0
2071,obligated,1.0
2072,pay,1.0
2073,achieved,1.0
2074,quarter,1.0
2075,amortized,1.0
2076,preparation,1.0
2077,determination,1.0
2078,computed,1.0
2079,calculated,1.0
2080,adjusted,1.0
2081,excluded,1.0
2082,directors,1.0
2083,june,1.0
2084,refinanced,1.0
2085,sum,1.0
2086,accrue,1.0
2087,addition,1.0
2088,reason,1.0
2089,itsfunding,1.0
2090,anniversarythrough,1.0
2091,and1,1.0
2092,warranties,1.0
2093,engaging,1.0
2094,mergers,1.0
2095,acquisitions,1.0
2096,distributions,1.0
2097,solely,1.0
2098,benefit,1.0
2099,qualified,1.0
2100,execution,1.0
2101,bankruptcy,1.0
2102,failure,1.0
2103,observe,1.0
2104,covenant,1.0
2105,cases,1.0
2106,cured,1.0
2107,occurrence,1.0
2108,vii,1.0
2109,viii,1.0
2110,attached,1.0
2111,seized,1.0
2112,remedies,1.0
2113,taking,1.0
2114,possession,1.0
2115,expiring,1.0
2116,volatilities,1.0
2117,comparison,1.0
2118,prepaying,1.0
2119,extinguishment,1.0
2120,sold,1.0
2121,file,1.0
2122,black,1.0
2123,developed,1.0
2124,estimating,1.0
2125,estimate,1.0
2126,established,1.0
2127,arise,1.0
2128,vest,1.0
2129,landlord,1.0
2130,insignificant,1.0
2131,member,1.0
2132,sboard,1.0
2133,codm,1.0
2134,president,1.0
2135,jersey,1.0
2136,shown,1.0
2137,tables,1.0
2138,additionally,1.0
2139,to24,1.0
2140,800shares,1.0
2141,part,1.0
2142,cite,1.0
2143,concerns,1.0
2144,things,1.0
2145,resolved,1.0
2146,brought,1.0
2147,june,1.0
2148,labeled,1.0
2149,conditioned,1.0
2150,ending,1.0
2151,case,1.0
2152,february 1,1.0
2153,mandatory,1.0
2154,february 17,1.0
2155,alter,1.0
2156,divided,1.0
2157,drawdown,1.0
2158,board,1.0
2159,june,1.0
2160,discussion,1.0
2161,analysis,1.0
2162,form10,1.0
2163,meaning,1.0
2164,section27a,1.0
2165,section21e,1.0
2166,predictions,1.0
2167,forecasts,1.0
2168,variations,1.0
2169,absence,1.0
2170,words,1.0
2171,limitation,1.0
2172,outlook,1.0
2173,objectives,1.0
2174,intentions,1.0
2175,goals,1.0
2176,enable,1.0
2177,intend,1.0
2178,safe,1.0
2179,caution,1.0
2180,relying,1.0
2181,guarantees,1.0
2182,assurances,1.0
2183,examples,1.0
2184,satisfaction,1.0
2185,requests,1.0
2186,build,1.0
2187,success,1.0
2188,timeframe,1.0
2189,labeling,1.0
2190,achievement,1.0
2191,progress,1.0
2192,acceptability,1.0
2193,purpose,1.0
2194,payers,1.0
2195,concurrence,1.0
2196,comparability,1.0
2197,respect,1.0
2198,pharmaceutical,1.0
2199,susceptible,1.0
2200,limit,1.0
2201,distributing,1.0
2202,profitable,1.0
2203,april,1.0
2204,filings,1.0
2205,speak,1.0
2206,undertake,1.0
2207,heading,1.0
2208,achieve,1.0
2209,affected,1.0
2210,manage,1.0
2211,difficulties,1.0
2212,delays,1.0
2213,caused,1.0
2214,prospects,1.0
2215,approve,1.0
2216,permit,1.0
2217,proceed,1.0
2218,enter,1.0
2219,uncertainty,1.0
2220,unable,1.0
2221,discontinue,1.0
2222,cautioned,1.0
2223,document,1.0
2224,prove,1.0
2225,accurate,1.0
2226,late,1.0
2227,caring,1.0
2228,cytomegalovirus,1.0
2229,cmv,1.0
2230,measles,1.0
2231,tetanus,1.0
2232,addressing,1.0
2233,deficient,1.0
2234,hereditary,1.0
2235,age,1.0
2236,gender,1.0
2237,vulnerable,1.0
2238,cells,1.0
2239,body,1.0
2240,bacteria,1.0
2241,viruses,1.0
2242,8 billion,1.0
2243,follow,1.0
2244,fifty,1.0
2245,enrolled,1.0
2246,reduction,1.0
2247,incidence,1.0
2248,pharmacokinetic,1.0
2249,agents,1.0
2250,sbi,1.0
2251,administered,1.0
2252,793 infusions,1.0
2253,requirement,1.0
2254,1 sbi,1.0
2255,february 22,1.0
2256,allergy,1.0
2257,work,1.0
2258,002 ranged,1.0
2259,immunoglobulins,1.0
2260,mild,1.0
2261,cold,1.0
2262,symptoms,1.0
2263,children,1.0
2264,death,1.0
2265,randomized,1.0
2266,double,1.0
2267,blind,1.0
2268,canada,1.0
2269,australia,1.0
2270,zealand,1.0
2271,compared,1.0
2272,observed,1.0
2273,april,1.0
2274,february 2011,1.0
2275,15 compassionate,1.0
2276,treating,1.0
2277,onset,1.0
2278,diagnosis,1.0
2279,tolerated,1.0
2280,reports,1.0
2281,compassionate,1.0
2282,conferences,1.0
2283,hire,1.0
2284,small,1.0
2285,hospitals,1.0
2286,logistics,1.0
2287,network,1.0
2288,uspto,1.0
2289,721 entitled,1.0
2290,compositions,1.0
2291,extends,1.0
2292,blending,1.0
2293,standardization,1.0
2294,garner,1.0
2295,000 liters,1.0
2296,quantity,1.0
2297,locationswhere,1.0
2298,royalty,1.0
2299,retain,1.0
2300,costly,1.0
2301,probability,1.0
2302,variety,1.0
2303,program,1.0
2304,competition,1.0
2305,determine,1.0
2306,maintenance,1.0
2307,utilities,1.0
2308,travel,1.0
2309,2016 compared,1.0
2310,relates,1.0
2311,site,1.0
2312,advertising,1.0
2313,remainder,1.0
2314,write,1.0
2315,repayment,1.0
2316,purchases,1.0
2317,prepayments,1.0
2318,decreases,1.0
2319,computers,1.0
2320,february 2012,1.0
2321,suppliers,1.0
2322,interactions,1.0
2323,aggressively,1.0
2324,execute,1.0
2325,predict,1.0
2326,certainty,1.0
2327,decide,1.0
2328,interests,1.0
2329,decline,1.0
2330,industries,1.0
2331,businesses,1.0
2332,suffering,1.0
2333,lack,1.0
2334,severity,1.0
2335,february 2016,1.0
2336,topic,1.0
2337,evaluating,1.0
2338,november 2015,1.0
2339,topic,1.0
2340,retrospectively,1.0
2341,topic,1.0
2342,simplifying,1.0
2343,changesto,1.0
2344,disclose,1.0
2345,topic,1.0
2346,context,1.0
2347,measures,1.0
2348,entitled,1.0
2349,steps,1.0
2350,april,1.0
2351,jumpstart,1.0
2352,law,1.0
2353,section,1.0
2354,advantage,1.0
2355,longer,1.0
2356,affirmatively,1.0
2357,elected,1.0
2358,comply,1.0
2359,applies,1.0
2360,adopt,1.0
2361,base,1.0
2362,sources,1.0
2363,experiences,1.0
2364,considered,1.0
2365,understanding,1.0
2366,award,1.0
2367,straight,1.0
2368,account,1.0
2369,revalued,1.0
2370,officers,1.0
2371,utilized,1.0
2372,dividends,1.0
2373,examining,1.0
2374,disposition,1.0
2375,lattice,1.0
2376,collaborate,1.0
2377,address,1.0
2378,awaiting,1.0
2379,feedback,1.0
2380,agency,1.0
2381,timeline,1.0
2382,practicable,1.0
2383,topic,1.0
2384,whichprovides,1.0
2385,simplification,1.0
2386,aspects,1.0
2387,assessing,1.0
2388,august2014,1.0
2389,subtopic 205,1.0
2390,determining,1.0
2391,enhance,1.0
2392,timeliness,1.0
2393,clarity,1.0
2394,consistency,1.0
2395,ifrs,1.0
2396,responsibility,1.0
2397,performing,1.0
2398,ifrss,1.0
2399,december15,1.0
2400,entry,1.0
2401,rationale,1.0
2402,attributed,1.0
2403,focus,1.0
2404,receipt,1.0
2405,deferring,1.0
2406,generation,1.0
2407,productrevenues,1.0
2408,finisher,1.0
2409,florida,1.0
2410,remediate,1.0
2411,june,1.0
2412,recoverability,1.0
2413,definition,1.0
2414,clarifies,1.0
2415,disposals,1.0
2416,screen,1.0
2417,contribute,1.0
2418,output,1.0
2419,evaluated,1.0
2420,jerrold,1.0
2421,adam,1.0
2422,members,1.0
2423,buyer,1.0
2424,assume,1.0
2425,buildings,1.0
2426,signing,1.0
2427,deliver,1.0
2428,excess,1.0
2429,designate,1.0
2430,contributed,1.0
2431,mortgage,1.0
2432,166 earnest,1.0
2433,premises,1.0
2434,utilize,1.0
2435,inclusive,1.0
2436,expiration,1.0
2437,refers,1.0
2438,sections,1.0
2439,chemistry,1.0
2440,controls,1.0
2441,cmc,1.0
2442,remediating,1.0
2443,relaunch,1.0
2444,locations,1.0
2445,2017 compared,1.0
2446,anticipation,1.0
2447,increasing,1.0
2448,hours,1.0
2449,redemptions,1.0
2450,repayments,1.0
2451,buildout,1.0
2452,forced,1.0
2453,$1 billion,1.0
2454,exempt,1.0
2455,june,1.0
2456,clients,1.0
2457,rich,1.0
2458,hbsag,1.0
2459,hbs,1.0
2460,% liquid,1.0
2461,refile,1.0
2462,exploring,1.0
2463,structuring,1.0
2464,found,1.0
2465,occurred,1.0
2466,intermediates,1.0
2467,reflected,1.0
2468,amends,1.0
2469,types,1.0
2470,specifically,1.0
2471,topic,1.0
2472,removes,1.0
2473,compare,1.0
2474,comparing,1.0
2475,exceed,1.0
2476,outlines,1.0
2477,supersedes,1.0
2478,judgment,1.0
2479,applying,1.0
2480,april,1.0
2481,topic,1.0
2482,clarify,1.0
2483,narrow,1.0
2484,clarification,1.0
2485,impacts,1.0
2486,modifications,1.0
2487,clarifications,1.0
2488,land,1.0
2489,plant,1.0
2490,assigned,1.0
2491,adolescents,1.0
2492,assess,1.0
2493,hypotension,1.0
2494,hepatic,1.0
2495,ready,1.0
2496,pat,1.0
2497,app,1.0
2498,serial,1.0
2499,allowed,1.0
2500,inclusion,1.0
